細胞名稱

人口腔鱗狀細胞癌細胞Ca9-22

貨物編碼

BFN60808616

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研      2類

培養體系

DMEM高糖+10%FBS+1%三抗

培養溫度

37℃

二氧化碳濃度

5%

簡介

人口腔鱗狀細胞癌細胞Ca9-22取自43歲男性供體。有報道顯示該細胞源頭被MSK-922細胞所污染，細胞*力下降，請各位學者注意。該細胞由我庫引種自JCRB，經過STR驗證。

注釋

Problematic cell line: Partially contaminated. Some stocks of Ca9-22 are contaminated with MSK-922 (PubMed=21868764).

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00437.

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

基因突變

TP53 p.Arg248Trp (c.742C>T) (PubMed=1570156; PubMed=10741724).

HLA信息

Class I

HLA-A        A*02:07,24:02

HLA-B        B*35,46:01

HLA-C        C*01:02,14:02

STR信息

Amelogenin        X,Y

CSF1PO        12

D5S818        12

D7S820        11,13

D13S317        11

D16S539        9,10

TH01        6

TPOX        8,11

vWA        16

參考文獻

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690

Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.

Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.

Clin. Cancer Res. 17:7248-7264(2011)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=29156801; DOI=10.18632/oncotarget.21174

Kalu N.N., Mazumdar T., Peng S., Shen L., Sambandam V., Rao X., Xi Y., Li L., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.

Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.

Oncotarget 8:86369-86383(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)